Sunday, February 25, 2024
spot_img
HomeStocks NewsDrugmaker Gilead to acquire CymaBay for $4.3 billion

Drugmaker Gilead to acquire CymaBay for $4.3 billion

The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar for the treatment of primary biliary cholangitis, a type of chronic inflammatory liver disease.

CymaBay had submitted a marketing application to the U.S. Food and Drug Administration (FDA) for the drug in December.

Shares of CymaBay were halted ahead of the announcement in premarket hours.

RELATED ARTICLES

Most Popular

Recent Comments